Open Access Rheumatology: Research and Reviews podcast

Biosimilars for Rheumatoid Arthritis - Riding the 2023 Wave

This podcast will discuss concerns patients may have about initiating treatment with a biosimilar, or switching from their current medication to a biosimilar, for Rheumatoid Arthritis. This includes:
• Defining biosimilar, interchangeable, and switching.
• Discussing data supporting the safety and efficacy of biosimilars in patients with Rheumatoid Arthritis.
• Discussing biosimilars to adalimumab that will become available in the United States in 2023.